

Featuring BJI Researchers
& CMHR CBJC Awardees.

[Enter Zoom Room Here](#)

BJI Members working to disseminate their research highlights within the Institute. Showcase Series are open to both Faculty and Trainee presentors. To be included in the series, please contact westerns.bji@uwo.ca directly.



Dr. David Walton

"Getst" - BJI's working group and application to the Indigenous Learning Fund.

Join Dr. Walton and members of the BJI "Get Everyone Started - Indigenous Training Initiative - GETSIT" (pronounced "Get's It") working group. Early assessments revealed that BJI members as a collective do not have adequate knowledge, partnerships and/or training opportunities to support self-reflection and learning about Indigenous ways of knowing, land-based learning and research approaches. Current capacity and interest among members are key considerations as BJI tries to support Indigenous learning within our MSK culture in a sustainable way. The goal of the GETSIT initiative is to raise awareness and build capacity by looking at what we do in a different way.



Dr. Harvi Hart

"Walk smarter not harder"

Lower walking cadence (i.e., steps/min) is associated with greater future joint damage in people with knee osteoarthritis—presumably due to higher cumulative knee loading. Higher knee loads are associated with knee osteoarthritis progression and knee pain. This study tested the hypothesis that higher walking cadence is associated with lower surrogate measures of knee loads in patients with knee osteoarthritis.



Dr. Beth Gillies

"PPAR-delta inhibitors for the treatment of osteoarthritis - Lessons learned in intra-articular drug delivery"

Osteoarthritis (OA) currently affects nearly 5 million Canadians and is a leading cause of chronic disability. There is currently no cure or disease-modifying therapy for OA. Research in our laboratories has shown that blocking a receptor called peroxisome proliferator-activated receptor delta may provide protective and therapeutic effects for OA. PPAR-delta inhibitors are known, but cannot be given orally due to potential side effects in other organs. The aim of our project is to develop a delivery system that will allow PPAR-delta inhibitors to be delivered directly to joints by an injection and then released there over a period of 3 months. This presentation will describe our progress towards this goal.

This showcase is open to the University Community.
Please feel free to share this invitation with colleagues or members of your lab/department.

Those interested in suggesting new workshop areas have an opportunity to do so online at:
http://boneandjoint.uwo.ca/how_to